Wall Street analyst price targets, ratings consensus & upside potential
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Protalix BioTherapeutics, Inc. (PLX) has a Wall Street consensus price target of N/A, based on estimates from 7 covering analysts. The company has a market capitalization of $218M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PLX trades at a trailing P/E of 78.7x and forward P/E of 14.4x. Analysts expect EPS to grow +199.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $19.18, with bear and bull scenarios of $-73.63 and $6.73 respectively. Model confidence stands at 25/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PLX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for PLX is $N/A, close to the current price of $2.88 (N/A% implied move). Based on 7 analyst estimates, the stock appears fairly valued near current levels.
PLX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 14.4x, PLX trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for PLX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $7 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PLX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PLX stock forecast based on 7 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $19, with bear/bull scenarios of $-74/$7.
Our quantitative valuation model calculates PLX's fair value at $19 (base case), with a bear case of $-74 and bull case of $7. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 25/100.
PLX trades at a forward P/E ratio of 14.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 78.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
PLX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PLX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $-74-$7 range provides an independent fundamental perspective.